ArticleMolecular medicine reports2019
Early intervention with gastrodin reduces striatal neurotoxicity in adult rats with experimentally‑induced diabetes mellitus.
Article in Molecular medicine reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- Six New Phenolic Compounds in Ethyl Acetate Extract of Tall Gastrodia Tuber (Tianma) with Four Compounds Screened Preliminarily for Cytoprotective Effects Against Excitotoxicity.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Gastrodin inhibits the formation of ataxin-3 aggregates by regulating the level of ERK1/2/P38 proteins.Orphanet journal of rare diseases · 2026Article
- Gastrodin, a Promising Natural Small Molecule for the Treatment of Central Nervous System Disorders, and Its Recent Progress in Synthesis, Pharmacology and Pharmacokinetics.International journal of molecular sciences · 2024Review
- Gastrodin: a comprehensive pharmacological review.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- A review: Mechanism and prospect of gastrodin in prevention and treatment of T2DM and COVID-19.Heliyon · 2023Review
- Review on pharmacological effects of gastrodin.Archives of pharmacal research · 2023Review
- Gastrodin ameliorates cognitive dysfunction in diabetes by inhibiting PAK2 phosphorylation.Aging · 2023Article
- Gastrodin and Vascular Dementia: Advances and Current Perspectives.Evidence-based complementary and alternative medicine : eCAM · 2022Review
- Identification of Potential Core Genes for the Rupture of Intracranial Aneurysms by a Bioinformatics Analysis.Frontiers in genetics · 2022Article
- Intervention of Gastrodin in Type 2 Diabetes Mellitus and Its Mechanism.Frontiers in pharmacology · 2021Article
- Mechanisms Underlying Gastrodin Alleviating Vincristine-Induced Peripheral Neuropathic Pain.Frontiers in pharmacology · 2021Article
- Early Intervention of Gastrodin Improved Motor Learning in Diabetic Rats Through Ameliorating Vascular Dysfunction.Neurochemical research · 2020Article
- Gastrodin Ameliorates Motor Learning Deficits Through Preserving Cerebellar Long-Term Depression Pathways in Diabetic Rats.Frontiers in neuroscience · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glutamate‑induced excitotoxicity in the striatum has an important role in neurodegenerative diseases. It has been reported that diabetes mellitus (DM) induces excitotoxicity in striatal neurons, although the underlying mechanism remains to be fully elucidated. The present study aimed to investigate the effect of gastrodin on DM‑induced excitotoxicity in the striatal neurons of diabetic rats. Adult Sprague‑Dawley rats were divided into control, diabetic, and gastrodin intervention groups. Diabetes in the rats was induced with a single intraperitoneal injection of streptozotocin (65 mg/kg). In the gastrodin groups, the rats were gavaged with 60 or 120 mg/kg/day gastrodin for 6 weeks, 3 weeks following the induction of diabetes. Pathological alterations in the striatum were assessed using hematoxylin and eosin (H&E) staining. The protein expression levels of phosphorylated (p)‑extracellular signal‑regulated kinase (ERK)1/2, p‑mitogen‑activated protein kinase kinase (MEK)1/2, tyrosine receptor kinase B (TrKB) and brain‑derived neurotrophic factor (BDNF) in the striatal neurons were evaluated by western blotting and double immunofluorescence. Additionally, the extracellular levels of glutamate were measured by microanalysis followed by high‑pressure‑liquid‑chromatography. In diabetic rats, striatal neuronal degeneration was evident following H&E staining, which revealed the common occurrence of pyknotic nuclei. This was coupled with an increase in glutamate levels in the striatal tissues. The protein expression levels of p‑ERK1/2, p‑MEK1/2, TrKB and BDNF in the striatal tissues were significantly increased in the diabetic rats compared with those in the normal rats. In the gastrodin groups, degeneration of the striatal neurons was ameliorated. Furthermore, the expression levels of glutamate, p‑ERK1/2, p‑MEK1/2, TrKB and BDNF in the striatal neurons were decreased. From these findings, it was concluded that reduced neurotoxicity in striatal neurons following treatment with gastrodin may be attributed to its suppressive effects on the expression of p‑ERK1/2, p‑MEK1/2, BDNF and TrKB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.